読み込み中
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
前日終値
$12.70
+$0.11 · +0.87%
時間外
$12.70
$0.00 · 0.00%
10月8日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日中レンジ
現在 $12.70
52週レンジ
現在 $12.70
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
64
割安
センチメント
74
強気
リスク
62
高リスク
モメンタム
66
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
日中レンジ
現在 $12.70
52週レンジ
現在 $12.70
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 8520.9万 USD | 3.7万 USD | 2072.3万 USD | 312.9万 USD | 1803.8万 USD |
| 売上原価 | 762.5万 USD | 1.41億 USD | 9709.6万 USD | 8025.3万 USD | 6136万 USD |
| 粗利益 | 7758.4万 USD | −1.41億 USD | −7637.3万 USD | −7712.4万 USD | −4332.2万 USD |
| 研究開発 | 1.96億 USD | 1.41億 USD | 9709.6万 USD | 8025.3万 USD | 6136万 USD |
| 販売・一般管理 | 4906万 USD | 4657.9万 USD | 3649.4万 USD | 3290.8万 USD | 2801.1万 USD |
| 営業費用 | 2.37億 USD | 4657.9万 USD | 3649.4万 USD | 3290.8万 USD | 2801.1万 USD |
| 受取利息 | 1947.5万 USD | 2705万 USD | 1221.1万 USD | 257.3万 USD | 13.7万 USD |
| 減価償却費と償却費 | 762.5万 USD | 670.5万 USD | 574.9万 USD | 388万 USD | 302万 USD |
| 営業利益 | −1.6億 USD | −1.88億 USD | −1.13億 USD | −1.1億 USD | −7133.3万 USD |
| 純利益 | −1.4億 USD | −1.61億 USD | −1.01億 USD | −1.07億 USD | −7131.7万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.67
上昇余地（133.62%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2241.42万0.00%2.3兆 USD0.03%$379.56-0.39%
State Street SPDR S&P Biotech ETFXBI1520.29万0.15%101.08億 USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM1515.3万0.02%776.97億 USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF658.81万0.01%954億 USD0.05%$233.13-0.15%
iShares Biotechnology ETFIBB477.23万0.05%104.14億 USD0.44%$200.48-1.41%
Dimensional - US Small Cap ETFDFAS386.14万0.01%336.6億 USD0.31%$78.10+0.23%
Vanguard Russell 2000 ETFVTWO371.61万0.02%180億 USD0.06%$112.1-0.10%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP353.59万0.13%26.36億 USD0.20%$65.61-1.19%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
